You have read all your free articles, to continue reading subscribe to read the rest of this content.
AstraZeneca today announced that MedImmune, its global biologics research and development arm, has entered into a licensing agreement with Allergan plc for the global rights to MEDI2070. MEDI2070 is an IL-23 monoclonal antibody currently in a Phase IIb clinical trial for moderate-to-severe CrohnâAlready a subscriber Login You have read all…
AstraZeneca has agreed to sell the rights to Crestor (rosuvastatin) and associated medicines in over 30 countries in Europe, except the UK and Spain, to Grünenthal. Crestor is a statin approved for the treatment of dyslipidaemia and hypercholesterolaemia. "This agreement supports the managemeAlready a subscriber Login You have read all…
Swedish Elypta announced last week that it is one of the winners in the EU program Horizon 2020 SME instrument phase 2 and has been awarded 2.35 million EUR. The grant will fund a multicenter trial for diagnoses of renal cell carcinoma (RCC), aimed at validating the company's metabolism-based liqAlready…
The company has received Advanced Therapy Medicinal Product (ATMP) classification from the European Medicines Agency (EMA) for the company’s lead cancer relapse vaccine candidate, DCP-001. DCP-001 is derived from Immunicum’s human DCOne cell line and is currently being evaluated as a cancer rAlready a subscriber Login You have read all…
